---
title: "Capricor Therapeutics, Inc. (CAPR.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/CAPR.US.md"
symbol: "CAPR.US"
name: "Capricor Therapeutics, Inc."
industry: "Biotechnology"
datetime: "2026-04-16T02:41:17.191Z"
locales:
  - [en](https://longbridge.com/en/quote/CAPR.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/CAPR.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/CAPR.US.md)
---

# Capricor Therapeutics, Inc. (CAPR.US)

## Company Overview

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and exosome platform program consists of engineered exosomes for vaccine and therapeutic development and is in preclinical trial. In addition, it engages in developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases; It has license agreement with Johns Hopkins University, University of Rome License, and Cedars-Sinai Medical Center to develop and commercialize licensed products and licensed services under the licensed patent rights in all fields and a nonexclusive right to the know-how; Cell Line License Agreement with Life Technologies for the development of exosomes platform.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.capricor.com](https://www.capricor.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-04-15T04:30:17.000Z

**Overall: D (0.73)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 0 / 393 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 0.00% |  |
| Net Profit YoY | -159.58% |  |
| P/B Ratio | 5.87 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 1795665452.00 |  |
| Revenue | 0.00 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -107.79% | E |
| Profit Margin | -736.62% | E |
| Gross Margin | 0.00% | E |
| Revenue YoY | -52.08% | E |
| Net Profit YoY | -140.35% | E |
| Total Assets YoY | 36.03% | A |
| Net Assets YoY | 22.86% | A |
| Cash Flow Margin | -13.58% | D |
| OCF YoY | -52.08% | E |
| Turnover | 0.10 | E |
| Gearing Ratio | 33.67% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Capricor Therapeutics, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "0.00%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-159.58%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "5.87",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "1795665452.00",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "0.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-107.79%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-736.62%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "0.00%",
          "rating": "E"
        },
        {
          "name": "Revenue YoY",
          "value": "-52.08%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-140.35%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "36.03%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "22.86%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "-13.58%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "-52.08%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.10",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "33.67%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -17.25 | 485/393 | - | - | - |
| PB | 5.93 | 336/393 | 15.11 | 3.67 | 2.76 |
| PS (TTM) | 141.72 | - | 123.37 | 26.88 | 21.34 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | MiMedx (MDXG.US) | A | B | A | B | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | B | B | A |
| 04 | CapForce Inc. (CFOR.US) | B | A | A | A | C | A |
| 05 | Vertex Pharma (VRTX.US) | A | B | C | B | C | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-04-14T04:00:00.000Z

Total Analysts: **10**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 8 | 80% |
| Overweight | 2 | 20% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 35.04 |
| Highest Target | 63.00 |
| Lowest Target | 43.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/CAPR.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/CAPR.US/norm.md)
- [Related News](https://longbridge.com/en/quote/CAPR.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/CAPR.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**